Pieris Pharmaceuticals, Inc. announced that Dr. Ann Barbier has joined the Company’s Board of Directors. Dr. Barbier is the Chief Medical Officer of Translate Bio. Prior to joining Translate Bio, Dr. Barbier was Vice President of Clinical Development, Rare Genetic Diseases, at Agios Pharmaceuticals, where she led the development program of a small molecule in rare benign hematological diseases. Previously, Dr. Barbier spent seven years at Shire, most recently as Global Clinical Development Lead and Senior Medical Director, where she worked on a variety of rare genetic diseases. Her prior experience includes positions at Envivo, Johnson & Johnson and Aventis. Dr. Barbier received her M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis. Commenting on the announcement Dr. Barbier stated: “I am thrilled to join the Board of Directors of Pieris at this exciting time for the Company. Pieris is in the midst of a rapid phase of growth, including ongoing clinical studies for three of its drug candidates in trials across the globe. I look forward to working with my fellow Directors and the Pieris management team to continue to advance the Company’s proprietary and codevelopment programs into and through the clinic.”

About Pieris Pharmaceuticals
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-lifeoptimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.